The EASL Breakdown: Key Highlights from the European Liver Conference
11/04/2026
In this Chronic Liver Disease Foundation (CLDF) educational program, leading hepatology experts Dr. Ira Jacobson, Dr. Paul Kwo, and Dr. Tatyana Kushner explore the latest advances in hepatitis B (HBV) and hepatitis D (HDV) treatment, highlighting key clinical trial data presented at the European Association for the Study of the Liver (EASL) Congress 2026. The discussion examines emerging therapies aimed at achieving a functional cure for chronic hepatitis B, including pivotal Phase 3 B-Well trial results for bepirovirsen, the importance of quantitative hepatitis B surface antigen (HBsAg) testing in identifying eligible patients, and promising investigational approaches such as antisense oligonucleotides, epigenetic silencing, and gene-editing technologies targeting HBV DNA. The faculty also review advances in hepatitis D management, including clinical trial and real-world evidence for bulevirtide, emerging investigational therapies, treatment response rates, safety considerations, and the potential role of combination therapy. Throughout the program, the experts provide clinical perspectives on HBV and HDV screening, treatment selection, long-term viral suppression, and shared decision-making. Healthcare professionals, including hepatologists, gastroenterologists, and advanced practice providers (APPs), will gain valuable insights into evolving hepatitis B and hepatitis D treatment strategies, emerging clinical evidence, and the future of chronic viral hepatitis management.
Watch Now